tiprankstipranks
Advertisement
Advertisement

SKYE Stock Latest News

Skye Bioscience Faces Nasdaq Listing Compliance Deficiency Notice
Company AnnouncementsSkye Bioscience Faces Nasdaq Listing Compliance Deficiency Notice
21d ago
8K
SKYE
SKYE Bioscience: Advancing Nimacimab Dose Expansion and Clear Phase 2b Path as Adjunct to Semaglutide Supports Buy Rating
PremiumRatings
SKYE Bioscience: Advancing Nimacimab Dose Expansion and Clear Phase 2b Path as Adjunct to Semaglutide Supports Buy Rating
29d ago
SKYE
Skye Bioscience reports Q4 EPS (36c), consensus (31c)
PremiumThe Fly
Skye Bioscience reports Q4 EPS (36c), consensus (31c)
30d ago
SKYE
SKYE Upcoming Earnings Report: What to Expect?
PremiumPre-Earnings
SKYE Upcoming Earnings Report: What to Expect?
1M ago
SKYE
Skye Bioscience: Nimacimab’s Emerging Clinical Profile and Undervalued Asymmetric Risk/Reward Support Buy Rating
PremiumRatings
Skye Bioscience: Nimacimab’s Emerging Clinical Profile and Undervalued Asymmetric Risk/Reward Support Buy Rating
2M ago
SKYE
Skye Bioscience Reports Promising Phase 2a Obesity Data
PremiumCompany AnnouncementsSkye Bioscience Reports Promising Phase 2a Obesity Data
2M ago
8K
SKYE
Skye Bioscience announces 52-week data from Phase 2a CBeyond study of nimacimab
Premium
The Fly
Skye Bioscience announces 52-week data from Phase 2a CBeyond study of nimacimab
2M ago
SKYE
Skye Bioscience presents poster on efficacy of Nimacimab
Premium
The Fly
Skye Bioscience presents poster on efficacy of Nimacimab
2M ago
SKYE
Vanguard Total Stock Market ETF (VTI) Daily Snapshot—1/14/26
PremiumMarket News
Vanguard Total Stock Market ETF (VTI) Daily Snapshot—1/14/26
3M ago
CLB
VTI
Skye Bioscience provides 2026 corporate outlook
PremiumThe Fly
Skye Bioscience provides 2026 corporate outlook
3M ago
SKYE
What Investors Can Learn from the Skye Bioscience Securities Fraud Allegations: A Risk Assessment Guide
PremiumClass Action
What Investors Can Learn from the Skye Bioscience Securities Fraud Allegations: A Risk Assessment Guide
3M ago
SKYE
VTI ETF Daily Update — 1/7/26
PremiumMarket News
VTI ETF Daily Update — 1/7/26
3M ago
RPT
VTI
Skye Bioscience: ENHANZE Partnership Unlocks Nimacimab Dosing, De-Risks Phase 2b Path and Supports Buy Rating
PremiumRatingsSkye Bioscience: ENHANZE Partnership Unlocks Nimacimab Dosing, De-Risks Phase 2b Path and Supports Buy Rating
3M ago
SKYE
Skye Bioscience, Halozyme enter collaboration, license agreement
Premium
The Fly
Skye Bioscience, Halozyme enter collaboration, license agreement
3M ago
HALO
SKYE
Halozyme, Skye Bioscience announce global collaboration, license agreement
Premium
The Fly
Halozyme, Skye Bioscience announce global collaboration, license agreement
3M ago
HALO
SKYE
Skye Bioscience Collaborates with Halozyme on Nimacimab Delivery
PremiumCompany Announcements
Skye Bioscience Collaborates with Halozyme on Nimacimab Delivery
4M ago
8K
SKYE
Skye Bioscience Faces Lawsuit Over Misleading Claims
PremiumClass Action
Skye Bioscience Faces Lawsuit Over Misleading Claims
5M ago
SKYE
Promising Adjunct Potential of Skye Bioscience’s Nimacimab Reinforces Buy Rating
PremiumRatings
Promising Adjunct Potential of Skye Bioscience’s Nimacimab Reinforces Buy Rating
5M ago
SKYE
Skye Bioscience Earnings Call: Mixed Signals with Promising Results
PremiumCompany Announcements
Skye Bioscience Earnings Call: Mixed Signals with Promising Results
5M ago
SKYE
Skye Bioscience Reports Promising Q3 2025 Results
PremiumCompany AnnouncementsSkye Bioscience Reports Promising Q3 2025 Results
5M ago
SKYE
Skye Bioscience reports Q3 EPS (32c), consensus (32c)
Premium
The Fly
Skye Bioscience reports Q3 EPS (32c), consensus (32c)
5M ago
SKYE
SKYE Earnings this Week: How Will it Perform?
Premium
Pre-Earnings
SKYE Earnings this Week: How Will it Perform?
5M ago
SKYE

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >